We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+0.99%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.03B
AUM Growth
-$7.04M
Cap. Flow
+$4.18M
Cap. Flow %
0.41%
Top 10 Hldgs %
43.95%
Holding
94
New
9
Increased
28
Reduced
9
Closed
24

Top Buys

Rank Stock Value
1
AMAG
AMAG Pharmaceuticals
AMAG
+$20.2M
2
AEGR
Aegerion Pharmaceuticals
AEGR
+$17.1M
3
UAM
Universal American Corp
UAM
+$12.2M
4
RAD
Rite Aid Corporation
RAD
+$11.8M
5
CORI
Corium International, Inc.
CORI
+$10.6M

Top Sells

Rank Stock Value
1
LCI
Lannett Company, Inc.
LCI
+$24.4M
2
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
+$21M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$14.9M
4
OCR
OMNICARE INC
OCR
+$10.4M
5
MOH icon
Molina Healthcare
MOH
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 79.79%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FLNA
76
Filana Therapeutics
FLNA
$43M
– –
-111,429
Closed -$4.29M
SRPT icon
77
Sarepta Therapeutics
SRPT
$1.66B
– –
-151,655
Closed -$3.64M
SSKN
78
DELISTED
Strata Skin Sciences
SSKN
– –
-8
Closed -$2.97M
TEVA icon
79
Teva Pharmaceuticals
TEVA
$35.9B
– –
-291,636
Closed -$14.9M
TLPH icon
80
Talphera
TLPH
$70.1M
– –
-10,000
Closed -$2.4M
TXMD icon
81
TherapeuticsMD
TXMD
$23.8M
– –
-9,177
Closed -$2.9M
ITCI
82
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-224,234
Closed -$4.08M
CUTR
83
DELISTED
Cutera, Inc.
CUTR
– –
-215,962
Closed -$2.42M
NSTG
84
DELISTED
NanoString Technologies, Inc.
NSTG
– –
-254,068
Closed -$5.25M
CNCE
85
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-200,000
Closed -$2.69M
LCI
86
DELISTED
Lannett Company, Inc.
LCI
– –
-170,891
Closed -$24.4M
VCRA
87
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
– –
-160,597
Closed -$2.62M
CORV
88
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
– –
-200,000
Closed -$1.58M
ACHN
89
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-1,000,000
Closed -$3.29M
NSPH
90
DELISTED
NANOSPHERE INC. COM NEW
NSPH
– –
-50,000
Closed -$2.15M
THOR
91
DELISTED
THORATEC CORPORATION
THOR
– –
-121,867
Closed -$4.36M
OCR
92
DELISTED
OMNICARE INC
OCR
– –
-175,000
Closed -$10.4M
CTRX
93
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
– –
-468,263
Closed -$21M
AIRM
94
DELISTED
Air Methods Corp
AIRM
– –
-100,000
Closed -$5.34M
1 2 3
4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q2 2014 Portfolio in Review

As of Q2 2014, Broadfin Capital held 94 positions worth $1.03B, down 0.68% from $1.03B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Broadfin Capital's Q2 2014 filing shows 9 new, 28 increased, 9 reduced and 24 closed positions. Its largest new stake was Rite Aid Corporation: 80,000 shares worth $11.5M. The largest sale was Lannett Company, Inc., an estimated $24.4M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 80% a quarter earlier, followed by Technology.

  • Broadfin Capital's largest Q2 2014 buy was Rite Aid Corporation: 80,000 shares worth $11.5M.
  • Broadfin Capital added most to AMAG Pharmaceuticals in Q2 2014, an estimated $20.2M increase.
  • Broadfin Capital's biggest Q2 2014 reduction was Assertio, cutting an estimated $9.23M.
  • Broadfin Capital fully exited Lannett Company, Inc. in Q2 2014, selling an estimated $24.4M.
  • Broadfin Capital's ten largest holdings make up 44% of its $1.03B portfolio in Q2 2014.
  • Broadfin Capital opened 9 new positions and closed 24 in Q2 2014.
  • Broadfin Capital's portfolio value fell 0.68% quarter-over-quarter to $1.03B.

Based on Broadfin Capital's 13F filing for Q2 2014, filed 14 Aug 2014.